Table 2

Intraoperative surgical and anaesthetic details

Propofol (n=25)Volatile (n=25)
Underwent surgery, n (%)24 (96%)24 (96%)
 Surgery duration, minMedian (IQR)240 (175–270)253 (210–285)
Missing data1 (4%)0 (0%)
 Cross-clamp time duration, minMedian (IQR)64 (53–82)63 (50–84)
Missing data1 (4%)1 (4%)
 Myocardial protection, n (%)Cardioplegia22 (88%)21 (84%)
Cross-clamp fibrillation2 (8%)3 (12%)
No surgery1 (4%)1 (4%)
 Procedure, n (%)CABG17 (68%)16 (64%)
CABG and valve7 (28%)8 (32%)
No surgery1 (4%)1 (4%)
 Number of grafts, n (%)13 (12%)1 (4%)
27 (28%)6 (24%)
310 (40%)12 (48%)
43 (12%)4 (16%)
51 (4%)1 (4%)
No surgery1 (4%)1 (4%)
Hypnotic agent
 During CPB, n (%)Propofol24 (96%)2 (8%)
Isoflurane0 (0%)22 (88%)
No surgery1 (4%)1 (4%)
Other anaesthetic management
 Analgesia, n (%)Fentanyl22 (88%)23 (92%)
Remifentanil20 (80%)11 (44%)
Morphine7 (28%)14 (56%)
No surgery1 (4%)1 (4%)
 Neuromuscular blocking agent, n (%)Atracurium3 (12%)6 (24%)
Rocuronium14 (56%)13 (52%)
Vecuronium2 (8%)2 (8%)
Pancuronium5 (20%)3 (12%)
No surgery1 (4%)1 (4%)
 Other medicationsTranexamic acid24 (96%)23 (92%)
Magnesium sulphate6 (24%)4 (16%)
No surgery1 (4%)1 (4%)
 Vasoactive medications, n (%)Any10 (40%)16 (64%)
Norepinephrine10 (40%)16 (64%)
Milrinone2 (8%)4 (16%)
Dobutamine1 (4%)1 (4%)
Epinephrine1 (4%)0 (0%)
Dopamine0 (0%)0 (0%)
Other3 (12%)1 (4%)
No surgery1 (4%)1 (4%)
  • If missing data not included as a row, all data collected.

  • CABG, coronary artery bypass graft; CPB, cardiopulmonary bypass.